Lynn B. Orriëns
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lynn B. Orriëns has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Corrie E. Erasmus
Department of Pediatric Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center Amalia Children's Hospital, Nijmegen, the Netherlands
8 shared publications - Karen van Hulst
Department of Rehabilitation, Amalia's Children Hospital, Donders Institute for Brain, Cognition and Behaviour Radboud University Medical Centre Nijmegen the Netherlands
8 shared publications - Frank J. A. van Den Hoogen
Ear, Nose and Throat department of Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands
4 shared publications - Michel A. A. P. Willemsen
Department of Pediatrics, Amalia Children’s Hospital, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
4 shared publications Frank J.A. van Den Hoogen
Department of Otorhinolaryngology and Head and Neck Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands
3 shared publications- Jan J. W. van der Burg
Department of Paediatric Rehabilitation, Sint Maartenskliniek, Nijmegen, the Netherlands
3 shared publications
Latest Publications
- Open Access
- 9 October 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 1-10
Understanding posterior drooling in children and young people with neurodevelopmental disabilities: a parental perspective
Saliva control problems in children and young people with neurodevelopmental disabilities are classified as anterior drooling (i.e. loss of saliva from the mouth) and posterior drooling (i.e. saliva spillage into the oropharynx). Posterior drooling poses serious health risks, but is often missed or misinterpreted. This study explored how parents perceive its symptoms and impact on daily life. Semi-structured focus group discussions were conducted with parents of children with posterior drooling, directed toward observable signs and impact on children as well as family. Sessions were recorded, transcribed, and thematically analysed. Three focus group sessions were conducted (total n = 12). Posterior drooling generally manifested across four domains: (1) head and throat, (2) airways, (3) stomach, and (4) whole body. The impact of posterior drooling encompassed effects on children’s well-being, social participation, independence, and interference with other conditions. For parents, posterior drooling posed practical, emotional, and social challenges and burdens – such as constant vigilance due to fear of choking, frustration about lack of effective treatment, and limited ability to participate in family or social activities – placing a considerable burden on daily life and caregiving. This qualitative study offers valuable initial insights into how parents characterise posterior drooling, shedding light on crucial information to enhance recognition and diagnosis. The findings underscore the need for earlier detection and identification of posterior drooling symptoms, supported by improved communication between healthcare professionals and families through a shared language that bridges clinical and everyday observations. The extensive impact on children and families also highlights the urgency of providing clearer guidance to parents on managing fluctuating or worsening symptoms, and of developing more comprehensive, tailored care strategies.
- 9 October 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 1-10
Open AccessUnderstanding posterior drooling in children and young people with neurodevelopmental disabilities: a parental perspective
Saliva control problems in children and young people with neurodevelopmental disabilities are classified as anterior drooling (i.e. loss of saliva from the mouth) and posterior drooling (i.e. saliva spillage into the oropharynx). Posterior drooling poses serious health risks, but is often missed or misinterpreted. This study explored how parents perceive its symptoms and impact on daily life. Semi-structured focus group discussions were conducted with parents of children with posterior drooling, directed toward observable signs and impact on children as well as family. Sessions were recorded, transcribed, and thematically analysed. Three focus group sessions were conducted (total n = 12). Posterior drooling generally manifested across four domains: (1) head and throat, (2) airways, (3) stomach, and (4) whole body. The impact of posterior drooling encompassed effects on children’s well-being, social participation, independence, and interference with other conditions. For parents, posterior drooling posed practical, emotional, and social challenges and burdens – such as constant vigilance due to fear of choking, frustration about lack of effective treatment, and limited ability to participate in family or social activities – placing a considerable burden on daily life and caregiving. This qualitative study offers valuable initial insights into how parents characterise posterior drooling, shedding light on crucial information to enhance recognition and diagnosis. The findings underscore the need for earlier detection and identification of posterior drooling symptoms, supported by improved communication between healthcare professionals and families through a shared language that bridges clinical and everyday observations. The extensive impact on children and families also highlights the urgency of providing clearer guidance to parents on managing fluctuating or worsening symptoms, and of developing more comprehensive, tailored care strategies.
- Open Access
- 7 September 2025
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 59, 1-10
The ins and outs of glycopyrronium treatment for paediatric drooling: exploring the treatment journey using real-world data
- 7 September 2025
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 59, 1-10
Open AccessThe ins and outs of glycopyrronium treatment for paediatric drooling: exploring the treatment journey using real-world data
- Open Access
- 1 April 2025
- Published by SAGE Publications in Journal of Pediatric Rehabilitation Medicine
- Vol. 18 (2) , 99-109
Reliability and validity of the Mini-Eating and Drinking Ability Classification System (Mini-EDACS) among Dutch preschoolers with cerebral palsy
Purpose: This study aimed to translate the English version of the Mini-Eating and Drinking Ability Classification System (Mini-EDACS) into Dutch and assess its psychometric properties and applicability among preschool-aged children with cerebral palsy (CP) in the Netherlands. Methods: Forty-eight children with CP (18–36 months) were included. Inter-rater reliability of the Dutch version of the Mini-EDACS was assessed between two speech and language therapists (SLTs) and between two SLTs and parents. Construct validity was established by hypothesis testing regarding the expected strength of the correlation between Mini-EDACS level and sum score of (a) the Pediatric Eating Assessment Tool (PEDI-EAT-10) and (b) the Montreal Children's Hospital Feeding Scale (MCH-FS). Results: The level of agreement for Mini-EDACS level was almost perfect between SLTs (weighted kappa (k w ) = 0.83) and substantial between parents and SLTs (parents vs SLT-1: k w = 0.77; parents vs SLT-2: k w = 0.70). Kendall's tau-b correlation between Mini-EDACS and PEDI-EAT-10 was 0.66 (p < 0.001), slightly lower than hypothesized, and 0.52 (p < 0.001) between Mini-EDACS and MCH-FS, aligning with the hypothesis. Applicability was found to be good. Conclusion: The Dutch version of the Mini-EDACS showed sufficient inter-rater reliability, construct validity and applicability and can be used in clinical care in the Netherlands to promote unambiguous communication between healthcare professionals and parents.
- 1 April 2025
- Published by SAGE Publications in Journal of Pediatric Rehabilitation Medicine
- Vol. 18 (2) , 99-109
Open AccessReliability and validity of the Mini-Eating and Drinking Ability Classification System (Mini-EDACS) among Dutch preschoolers with cerebral palsy
Purpose: This study aimed to translate the English version of the Mini-Eating and Drinking Ability Classification System (Mini-EDACS) into Dutch and assess its psychometric properties and applicability among preschool-aged children with cerebral palsy (CP) in the Netherlands. Methods: Forty-eight children with CP (18–36 months) were included. Inter-rater reliability of the Dutch version of the Mini-EDACS was assessed between two speech and language therapists (SLTs) and between two SLTs and parents. Construct validity was established by hypothesis testing regarding the expected strength of the correlation between Mini-EDACS level and sum score of (a) the Pediatric Eating Assessment Tool (PEDI-EAT-10) and (b) the Montreal Children's Hospital Feeding Scale (MCH-FS). Results: The level of agreement for Mini-EDACS level was almost perfect between SLTs (weighted kappa (k w ) = 0.83) and substantial between parents and SLTs (parents vs SLT-1: k w = 0.77; parents vs SLT-2: k w = 0.70). Kendall's tau-b correlation between Mini-EDACS and PEDI-EAT-10 was 0.66 (p < 0.001), slightly lower than hypothesized, and 0.52 (p < 0.001) between Mini-EDACS and MCH-FS, aligning with the hypothesis. Applicability was found to be good. Conclusion: The Dutch version of the Mini-EDACS showed sufficient inter-rater reliability, construct validity and applicability and can be used in clinical care in the Netherlands to promote unambiguous communication between healthcare professionals and parents.
- Open Access
- 24 October 2024
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 67 (5) , 656-664
Negative effects on oral motor function after submandibular and parotid botulinum neurotoxin A injections for drooling in children with developmental disabilities
Aim: To evaluate negative effects on oral motor function after concurrent submandibular and parotid (four‐gland) botulinum neurotoxin A (BoNT‐A) injections as a treatment for paediatric drooling.Method: This was a retrospective cohort study of 125 children (median age 7 years 7 months [interquartile range 4 years 5 months]) with developmental disabilities, including cerebral palsy, treated with four‐gland injections. Most children (90.4%) were previously exposed to submandibular injections. Frequency, severity, and duration of negative effects on oral motor function (i.e. saliva swallowing, eating, drinking, articulation) were evaluated and compared to a reference cohort treated with submandibular injections.Results: Negative effects on oral motor function were reported in 45 children (36.0%), predominantly manifesting as eating‐related problems (64.4%). Most negative effects (62.2%) were classified as mild and resolved within 4‐weeks post‐injunction (53.3%). Compared to the reference cohort, frequency (36.0% vs 33.0%) and duration (53.3% vs 53.6% resolving within 4 weeks) of negative effects were comparable, although problems were more often moderately severe (33.3% vs 10.1%).Interpretation: While negative effects on oral motor function were relatively common after four‐gland BoNT‐A injections, most problems were mild and resolved promptly. No substantial differences to a reference cohort treated with submandibular injections were observed, although further research should establish the generalizability of these findings in a treatment‐naive population. Nevertheless, when submandibular injections prove ineffective, clinicians can confidently consider four‐gland injections.
- 24 October 2024
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 67 (5) , 656-664
Open AccessNegative effects on oral motor function after submandibular and parotid botulinum neurotoxin A injections for drooling in children with developmental disabilities
Aim: To evaluate negative effects on oral motor function after concurrent submandibular and parotid (four‐gland) botulinum neurotoxin A (BoNT‐A) injections as a treatment for paediatric drooling.Method: This was a retrospective cohort study of 125 children (median age 7 years 7 months [interquartile range 4 years 5 months]) with developmental disabilities, including cerebral palsy, treated with four‐gland injections. Most children (90.4%) were previously exposed to submandibular injections. Frequency, severity, and duration of negative effects on oral motor function (i.e. saliva swallowing, eating, drinking, articulation) were evaluated and compared to a reference cohort treated with submandibular injections.Results: Negative effects on oral motor function were reported in 45 children (36.0%), predominantly manifesting as eating‐related problems (64.4%). Most negative effects (62.2%) were classified as mild and resolved within 4‐weeks post‐injunction (53.3%). Compared to the reference cohort, frequency (36.0% vs 33.0%) and duration (53.3% vs 53.6% resolving within 4 weeks) of negative effects were comparable, although problems were more often moderately severe (33.3% vs 10.1%).Interpretation: While negative effects on oral motor function were relatively common after four‐gland BoNT‐A injections, most problems were mild and resolved promptly. No substantial differences to a reference cohort treated with submandibular injections were observed, although further research should establish the generalizability of these findings in a treatment‐naive population. Nevertheless, when submandibular injections prove ineffective, clinicians can confidently consider four‐gland injections.
- Open Access
- 15 August 2024
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 183 (10) , 4491-4498
Social and emotional impact of anterior drooling in school-age children and young people with neurodevelopmental disabilities
Purpose: Anterior drooling is a common comorbidity in children and young people (CYP) with neurodevelopmental disabilities. This study aimed to assess the social and emotional impact of drooling in CYP with a developmental age (DA) of 6 years and older, in whom this impact may differ from those with a lower DA due to their developing sense of self and awareness of their position within social groups. Methods: Questionnaire data collected for routine clinical care were used to assess parental perceptions of the impact of drooling on (1) social interaction; (2) satisfaction with social interaction, appearance, family relations and life in general and (3) the way CYP expressed feelings on appearance, acceptance by peers and acceptance by adults. Fisher’s exact tests and Mann–Whitney U tests were applied to identify associations between clinical characteristics and the social and emotional impact of drooling. Results: Seventy-nine CYP with an estimated DA ≥ 6 years were included. The majority experienced frequent to constant (83%) and profuse (61%) drooling. Drooling frequently compromised social interaction with peers (49%) and adults (28%), and cognitive abilities were underestimated in 40%. Dissatisfaction with physical appearance (25%) related to drooling was noted. One-fifth of CYP reportedly expressed negative feelings on acceptance by peers related to drooling. Conclusions: These findings underscore the substantial impact of drooling on CYP with a DA of 6 years and older, primarily through avoidance by peers and underestimated cognitive abilities, emphasizing that recognizing and addressing these social-emotional consequences should be integral to clinical care. What is Known:• Anterior drooling is common among children and youth with neurodevelopmental disabilities. What is New:• There seems to be a heightened prevalence of impaired social interaction with peers and underestimation of cognitive abilities due to drooling among children with a developmental age of at least 6 years compared to previous studies with more heterogeneous populations.• The impact of drooling can extend to domains that affect self-esteem, although this may not be fully captured with standardized questions, requiring clinicians to address these consequences in a way that is tailored to the child’s experiences.
- 15 August 2024
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 183 (10) , 4491-4498
Open AccessSocial and emotional impact of anterior drooling in school-age children and young people with neurodevelopmental disabilities
Purpose: Anterior drooling is a common comorbidity in children and young people (CYP) with neurodevelopmental disabilities. This study aimed to assess the social and emotional impact of drooling in CYP with a developmental age (DA) of 6 years and older, in whom this impact may differ from those with a lower DA due to their developing sense of self and awareness of their position within social groups. Methods: Questionnaire data collected for routine clinical care were used to assess parental perceptions of the impact of drooling on (1) social interaction; (2) satisfaction with social interaction, appearance, family relations and life in general and (3) the way CYP expressed feelings on appearance, acceptance by peers and acceptance by adults. Fisher’s exact tests and Mann–Whitney U tests were applied to identify associations between clinical characteristics and the social and emotional impact of drooling. Results: Seventy-nine CYP with an estimated DA ≥ 6 years were included. The majority experienced frequent to constant (83%) and profuse (61%) drooling. Drooling frequently compromised social interaction with peers (49%) and adults (28%), and cognitive abilities were underestimated in 40%. Dissatisfaction with physical appearance (25%) related to drooling was noted. One-fifth of CYP reportedly expressed negative feelings on acceptance by peers related to drooling. Conclusions: These findings underscore the substantial impact of drooling on CYP with a DA of 6 years and older, primarily through avoidance by peers and underestimated cognitive abilities, emphasizing that recognizing and addressing these social-emotional consequences should be integral to clinical care. What is Known:• Anterior drooling is common among children and youth with neurodevelopmental disabilities. What is New:• There seems to be a heightened prevalence of impaired social interaction with peers and underestimation of cognitive abilities due to drooling among children with a developmental age of at least 6 years compared to previous studies with more heterogeneous populations.• The impact of drooling can extend to domains that affect self-esteem, although this may not be fully captured with standardized questions, requiring clinicians to address these consequences in a way that is tailored to the child’s experiences.
- Open Access
- 28 June 2024
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 183 (9) , 3979-3985
Interdisciplinary assessment and treatment of paediatric drooling: two decades of experience by the Nijmegen saliva control team reflected in a stepwise algorithm
Anterior and posterior drooling are prevalent comorbidities in children with neurodevelopmental disabilities. Considering the heterogeneity of the patient population and the multifactorial aetiology of drooling, an interdisciplinary and individualised treatment approach is indispensable. However, no tool for stepwise decision-making in the treatment of paediatric drooling has been developed previously. Within the Radboudumc Amalia Children’s Hospital, care for children with anterior and/or posterior drooling secondary to neurodevelopmental disabilities is coordinated by a saliva control team with healthcare professionals from six disciplines. In alignment with international literature, published guidelines, and evidence gained from two decades of experience and research by our team, this paper proposes an algorithm reflecting the assessment and treatment approach applied in our clinic. First, directions are provided to decide on the necessity of saliva control treatment, taking type of drooling, the child’s age, and the severity and impact of drooling into account. Second, the algorithm offers guidance on the choice between available treatment options, highlighting the importance of accounting for child characteristics and child and caregiver preferences in clinical (shared) decision-making.Conclusions: With this algorithm, we aim to emphasise the importance of repeated stepwise decision-making in the assessment and treatment of drooling in children during their childhood, encouraging healthcare professionals to apply a holistic approach. What is Known:• Children with anterior or posterior drooling secondary to neurodevelopmental disabilities comprise a heterogeneous group, necessitating an individualised treatment approach.• No stepwise decision-making tool is available for the treatment of paediatric drooling. What is New:• Deciding on the necessity of saliva control treatment should be a conscious process, based on type of drooling, age, and drooling severity and impact.• Type of drooling, age, cognition, oral motor skills, self-awareness, posture, diagnosis, and child/caregiver preferences need to be considered to decide on the optimal treatment.
- 28 June 2024
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 183 (9) , 3979-3985
Open AccessInterdisciplinary assessment and treatment of paediatric drooling: two decades of experience by the Nijmegen saliva control team reflected in a stepwise algorithm
Anterior and posterior drooling are prevalent comorbidities in children with neurodevelopmental disabilities. Considering the heterogeneity of the patient population and the multifactorial aetiology of drooling, an interdisciplinary and individualised treatment approach is indispensable. However, no tool for stepwise decision-making in the treatment of paediatric drooling has been developed previously. Within the Radboudumc Amalia Children’s Hospital, care for children with anterior and/or posterior drooling secondary to neurodevelopmental disabilities is coordinated by a saliva control team with healthcare professionals from six disciplines. In alignment with international literature, published guidelines, and evidence gained from two decades of experience and research by our team, this paper proposes an algorithm reflecting the assessment and treatment approach applied in our clinic. First, directions are provided to decide on the necessity of saliva control treatment, taking type of drooling, the child’s age, and the severity and impact of drooling into account. Second, the algorithm offers guidance on the choice between available treatment options, highlighting the importance of accounting for child characteristics and child and caregiver preferences in clinical (shared) decision-making.Conclusions: With this algorithm, we aim to emphasise the importance of repeated stepwise decision-making in the assessment and treatment of drooling in children during their childhood, encouraging healthcare professionals to apply a holistic approach. What is Known:• Children with anterior or posterior drooling secondary to neurodevelopmental disabilities comprise a heterogeneous group, necessitating an individualised treatment approach.• No stepwise decision-making tool is available for the treatment of paediatric drooling. What is New:• Deciding on the necessity of saliva control treatment should be a conscious process, based on type of drooling, age, and drooling severity and impact.• Type of drooling, age, cognition, oral motor skills, self-awareness, posture, diagnosis, and child/caregiver preferences need to be considered to decide on the optimal treatment.
- Open Access
- 16 May 2024
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 51, 24-31
The when, why, and how of using glycopyrronium to diminish drooling in children with neurodevelopmental disabilities: Implications for clinical practice
- 16 May 2024
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 51, 24-31
Open AccessThe when, why, and how of using glycopyrronium to diminish drooling in children with neurodevelopmental disabilities: Implications for clinical practice
- Open Access
- 23 December 2023
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 66 (7) , 919-930
Predicting non‐response to intraglandular botulinum neurotoxin A injections for drooling in children with neurodevelopmental disabilities
Aim: To develop robust multivariable prediction models for non‐response to (1) submandibular botulinum neurotoxin A (BoNT‐A) injections and (2) concurrent submandibular and parotid (four‐gland) injections, to guide treatment decisions for drooling in children with neurodevelopmental disabilities, including cerebral palsy.Method: This was a retrospective cohort study including 262 children (155 males/107 females, median age 7 years 11 months [IQR 5 years 1 month], range 4 years 0 months – 17 years 11 months) receiving submandibular injections and 74 children (52 males/22 females, median age 7 years 7 months [IQR 4 years 3 months], range 4 years 9 months – 18 years 8 months) receiving four‐gland injections. Multivariable logistic regression analyses were used to estimate associations between candidate predictors and non‐response 8 weeks after injection.Results: Ninety‐six children (37%) were non‐responders to submandibular injections, for which developmental age was the strongest predictor (adjusted odds ratio [aOR] 2.13; 95% confidence interval [CI] 1.02–4.45 for developmental age <4 years or 4–6 years with IQ <70). Other characteristics that showed a trend towards an increased risk of non‐response were diagnosis, sex, and head position. Thirty‐four children (46%) were non‐responders to four‐gland injections, for which tongue protrusion (aOR 3.10; 95% CI 1.14–8.43) seemed most predictive, whereas multiple preceding submandibular injections (aOR 0.34; 95% CI 0.10–1.16) showed a trend towards being protective. Predictors were, however, unstable across different definitions of non‐response and both models (i.e. submandibular and four‐gland) had insufficient discriminative ability.Interpretation: Potential predictors of non‐response to BoNT‐A injections were identified. Nevertheless, the developed prediction models seemed inadequate for guidance of treatment decisions.What this paper adds: Developmental age seemed most predictive of non‐response to submandibular botulinum neurotoxin A injections. Non‐response to concurrent submandibular and parotid injections was best predicted by tongue protrusion and number of previous injections. Multivariable prediction models including these clinical characteristics were unable to discriminate well. Predictors differed when non‐response was defined using alternative outcome measures.
- 23 December 2023
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 66 (7) , 919-930
Open AccessPredicting non‐response to intraglandular botulinum neurotoxin A injections for drooling in children with neurodevelopmental disabilities
Aim: To develop robust multivariable prediction models for non‐response to (1) submandibular botulinum neurotoxin A (BoNT‐A) injections and (2) concurrent submandibular and parotid (four‐gland) injections, to guide treatment decisions for drooling in children with neurodevelopmental disabilities, including cerebral palsy.Method: This was a retrospective cohort study including 262 children (155 males/107 females, median age 7 years 11 months [IQR 5 years 1 month], range 4 years 0 months – 17 years 11 months) receiving submandibular injections and 74 children (52 males/22 females, median age 7 years 7 months [IQR 4 years 3 months], range 4 years 9 months – 18 years 8 months) receiving four‐gland injections. Multivariable logistic regression analyses were used to estimate associations between candidate predictors and non‐response 8 weeks after injection.Results: Ninety‐six children (37%) were non‐responders to submandibular injections, for which developmental age was the strongest predictor (adjusted odds ratio [aOR] 2.13; 95% confidence interval [CI] 1.02–4.45 for developmental age <4 years or 4–6 years with IQ <70). Other characteristics that showed a trend towards an increased risk of non‐response were diagnosis, sex, and head position. Thirty‐four children (46%) were non‐responders to four‐gland injections, for which tongue protrusion (aOR 3.10; 95% CI 1.14–8.43) seemed most predictive, whereas multiple preceding submandibular injections (aOR 0.34; 95% CI 0.10–1.16) showed a trend towards being protective. Predictors were, however, unstable across different definitions of non‐response and both models (i.e. submandibular and four‐gland) had insufficient discriminative ability.Interpretation: Potential predictors of non‐response to BoNT‐A injections were identified. Nevertheless, the developed prediction models seemed inadequate for guidance of treatment decisions.What this paper adds: Developmental age seemed most predictive of non‐response to submandibular botulinum neurotoxin A injections. Non‐response to concurrent submandibular and parotid injections was best predicted by tongue protrusion and number of previous injections. Multivariable prediction models including these clinical characteristics were unable to discriminate well. Predictors differed when non‐response was defined using alternative outcome measures.
- Open Access
- 4 November 2023
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 183 (1) , 83-93
Comparing the evidence for botulinum neurotoxin injections in paediatric anterior drooling: a scoping review
Paediatric anterior drooling has a major impact on the daily lives of children and caregivers. Intraglandular botulinum neurotoxin type-A (BoNT-A) injections are considered an effective treatment to diminish drooling. However, there is no international consensus on which major salivary glands should be injected to obtain optimal treatment effect while minimizing the risk of side effects. This scoping review aimed to explore the evidence for submandibular BoNT-A injections and concurrent submandibular and parotid (i.e. four-gland) injections, respectively, and assess whether outcomes could be compared across studies to improve decision making regarding the optimal initial BoNT-A treatment approach for paediatric anterior drooling. PubMed, Embase, and Web of Science were searched to identify relevant studies (until October 1, 2023) on submandibular or four-gland BoNT-A injections for the treatment of anterior drooling in children with neurodevelopmental disabilities. Similarities and differences in treatment, patient, outcome, and follow-up characteristics were assessed. Twenty-eight papers were identified; 7 reporting on submandibular injections and 21 on four-gland injections. No major differences in treatment procedures or timing of follow-up were found. However, patient characteristics were poorly reported, there was great variety in outcome measurement, and the assessment of side effects was not clearly described. Conclusion: This review highlights heterogeneity in outcome measures and patient population descriptors among studies on paediatric BoNT-A injections, limiting the ability to compare treatment effectiveness between submandibular and four-gland injections. These findings emphasize the need for more extensive and uniform reporting of patient characteristics and the implementation of a core outcome measurement set to allow for comparison of results between studies and facilitate the optimization of clinical practice guidelines. What is Known:• There is no international consensus on which salivary glands to initially inject with BoNT-A to treat paediatric drooling. What is New:• Concluding on the optimal initial BoNT-A treatment based on literature is currently infeasible. There is considerable heterogeneity in outcome measures used to quantify anterior drooling.and clinical characteristics of children treated with intraglandular BoNT-A are generally insufficiently reported.• Consensus-based sets of outcome measures and patient characteristics should be developed and implemented.
- 4 November 2023
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 183 (1) , 83-93
Open AccessComparing the evidence for botulinum neurotoxin injections in paediatric anterior drooling: a scoping review
Paediatric anterior drooling has a major impact on the daily lives of children and caregivers. Intraglandular botulinum neurotoxin type-A (BoNT-A) injections are considered an effective treatment to diminish drooling. However, there is no international consensus on which major salivary glands should be injected to obtain optimal treatment effect while minimizing the risk of side effects. This scoping review aimed to explore the evidence for submandibular BoNT-A injections and concurrent submandibular and parotid (i.e. four-gland) injections, respectively, and assess whether outcomes could be compared across studies to improve decision making regarding the optimal initial BoNT-A treatment approach for paediatric anterior drooling. PubMed, Embase, and Web of Science were searched to identify relevant studies (until October 1, 2023) on submandibular or four-gland BoNT-A injections for the treatment of anterior drooling in children with neurodevelopmental disabilities. Similarities and differences in treatment, patient, outcome, and follow-up characteristics were assessed. Twenty-eight papers were identified; 7 reporting on submandibular injections and 21 on four-gland injections. No major differences in treatment procedures or timing of follow-up were found. However, patient characteristics were poorly reported, there was great variety in outcome measurement, and the assessment of side effects was not clearly described. Conclusion: This review highlights heterogeneity in outcome measures and patient population descriptors among studies on paediatric BoNT-A injections, limiting the ability to compare treatment effectiveness between submandibular and four-gland injections. These findings emphasize the need for more extensive and uniform reporting of patient characteristics and the implementation of a core outcome measurement set to allow for comparison of results between studies and facilitate the optimization of clinical practice guidelines. What is Known:• There is no international consensus on which salivary glands to initially inject with BoNT-A to treat paediatric drooling. What is New:• Concluding on the optimal initial BoNT-A treatment based on literature is currently infeasible. There is considerable heterogeneity in outcome measures used to quantify anterior drooling.and clinical characteristics of children treated with intraglandular BoNT-A are generally insufficiently reported.• Consensus-based sets of outcome measures and patient characteristics should be developed and implemented.
- Open Access
- 14 August 2023
- Published by Wiley in Acta Paediatrica
- Vol. 112 (11) , 2434-2439
Recognising symptoms of congenital myasthenic syndromes in children: A guide for paediatricians
Aim: Congenital myasthenic syndromes (CMS) are a rare and diverse group of treatable neuromuscular transmission disorders. Diagnosis is often substantially delayed. This study aimed to identify common symptoms of CMS in children and their manifestation to aid diagnosis and early intervention.Methods: We performed a retrospective cohort study, including 18 children (median age 13 years, range 9 years 5 months-18 years 0 month) with CMS. Data on CMS symptoms and their manifestation were extracted from patients' charts and supplemented with parental telephone interviews. Descriptive analyses were used to identify common symptoms.Results: A median diagnostic delay of 4 years and 7 months (interquartile range: 51 months) was observed. Proximal muscle weakness (100%), ptosis (89%), clumsy gait (82%), difficulty eating solid foods (78%) and recurrent respiratory tract infections (72%) were most common in these patients. Symptoms mostly co-occurred and frequently had a fluctuating character, aggravated by infections or fatigue.Conclusion: Early referral to diagnose CMS is crucial to enable timely initiation of treatment. Heightened attention to a combination of symptoms related to muscle weakness, rather than individual symptoms, should support paediatricians in flagging these neuromuscular disorders. Medical history taking should be tailored to parents' perceptions, asking questions about recognisable symptoms of muscle weakness.
- 14 August 2023
- Published by Wiley in Acta Paediatrica
- Vol. 112 (11) , 2434-2439
Open AccessRecognising symptoms of congenital myasthenic syndromes in children: A guide for paediatricians
Aim: Congenital myasthenic syndromes (CMS) are a rare and diverse group of treatable neuromuscular transmission disorders. Diagnosis is often substantially delayed. This study aimed to identify common symptoms of CMS in children and their manifestation to aid diagnosis and early intervention.Methods: We performed a retrospective cohort study, including 18 children (median age 13 years, range 9 years 5 months-18 years 0 month) with CMS. Data on CMS symptoms and their manifestation were extracted from patients' charts and supplemented with parental telephone interviews. Descriptive analyses were used to identify common symptoms.Results: A median diagnostic delay of 4 years and 7 months (interquartile range: 51 months) was observed. Proximal muscle weakness (100%), ptosis (89%), clumsy gait (82%), difficulty eating solid foods (78%) and recurrent respiratory tract infections (72%) were most common in these patients. Symptoms mostly co-occurred and frequently had a fluctuating character, aggravated by infections or fatigue.Conclusion: Early referral to diagnose CMS is crucial to enable timely initiation of treatment. Heightened attention to a combination of symptoms related to muscle weakness, rather than individual symptoms, should support paediatricians in flagging these neuromuscular disorders. Medical history taking should be tailored to parents' perceptions, asking questions about recognisable symptoms of muscle weakness.